BeiGene’s Brukinsa (zanubrutinib) Receives EC’s Approval for the Treatment of Waldenström’s Macroglobulinemia
Shots:
- The approval is based on the P-III ASPEN trial to evaluate Brukinsa vs ibrutinib in patients with WM who have received 1 prior therapy or were unsuitable for chemo-immunotherapy
- The results showed a combined rate of CR & VGPR in an overall ITT population (28% vs 19%), a favorable safety profile with lower frequency of adverse reactions, patient discontinuation due to AEs (4%) & trial fails to meet 1EPs of deep response or VGPR & showed clinical benefit
- Brukinsa is being evaluated globally in a broad clinical program as monothx. & in combination with other therapies for multiple B-cell malignancies. The approval is available to all 27 EU member states along with Iceland & Norway
Click here to read full press release
Ref: Businesswire | Image: BeiGene
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com